Skip to content
HowShorted

Puma Biotechnology Inc short interest in 2025

In 2025, Puma Biotechnology Inc's disclosed short interest ran from 6.26% of shares outstanding on 15 Jan 2025 to 6.84% on 31 Dec 2025, a change of +0.58 percentage points. The year's high was 6.98% on 30 Sep 2025 and its low 5.25% on 15 Jul 2025, averaging 6.09% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.54 days on 30 Apr 2025. Full history: Puma Biotechnology Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Puma Biotechnology Inc in 2025

2025 in figures

Start of year
6.26% (15 Jan 2025)
End of year
6.84% (31 Dec 2025)
Change
+0.58 pp
High
6.98% (30 Sep 2025)
Low
5.25% (15 Jul 2025)
Average
6.09%
Highest days to cover
12.54 (30 Apr 2025)
SEC filings marked
8

Every report in 2025

Puma Biotechnology Inc short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20256.26%2.78
31 Jan 20256.08%7.43
14 Feb 20256.25%12.34
28 Feb 20256.43%5.7110-K filed, results (8-K)
14 Mar 20255.69%5.91
31 Mar 20255.87%8.04
15 Apr 20255.84%8.22
30 Apr 20255.97%12.54
15 May 20255.78%7.4210-Q filed, results (8-K)
30 May 20255.61%8.14
13 Jun 20255.39%5.73
30 Jun 20255.31%8.71
15 Jul 20255.25%7.65
31 Jul 20255.61%9.09
15 Aug 20255.26%2.4410-Q filed, results (8-K)
29 Aug 20255.49%3.63
15 Sep 20256.74%6.28
30 Sep 20256.98%6.77
15 Oct 20256.67%7.07
31 Oct 20256.64%8.38
14 Nov 20256.61%3.6310-Q filed, results (8-K)
28 Nov 20256.77%8.42
15 Dec 20256.81%8.53
31 Dec 20256.84%9.61

See also: Puma Biotechnology Inc's full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.